Former United States Securities and Exchange Commission attorney Willie Briscoe and the securities litigation firm of Powers Taylor, LLP are investigating the sale of Palomar Medical Technologies, Inc. (“Palomar”) (NasdaqGS: PMTI) to Cynosure, Inc. for shareholders. Under the terms of the proposed transaction valued at approximately $294 million, Palomar shareholders will only receive $13.65 in consideration: $6.825 in cash and $6.825 in Cynosure common stock (subject to adjustment), for each share of Palomar stock owned, well below at least one analyst’s estimated value of $14.50 per share.
If you are an affected investor, and you want to learn more about the lawsuit or join the action, contact Willie Briscoe at The Briscoe Law Firm, PLLC, (214) 239-4568, or via email at WBriscoe@TheBriscoeLawFirm.com, or Zach Groover at Powers Taylor, LLP, toll free (877) 728-9607, via e-mail at firstname.lastname@example.org. There is no cost or fee to you.
The Palomar sale investigation centers on whether Palomar’s shareholders are receiving adequate compensation for their shares in the buyout, whether the transaction undervalues Palomar’s stock, and whether Palomar’s board attempted to obtain the highest share price for all shareholders prior to agreeing to the deal. Notably, at least one analyst with Yahoo! Finance has estimated that the true inherent value of Palomar shares could be as high as $14.50 per share. Shareholder rights attorney Patrick Powers stated that “due to proposed sale price, analysts’ estimates, the size of the deal and other factors, we believe this transaction may undervalue Palomar’s stock. Our proposed lawsuit will seek to ensure that shareholders are receiving the highest share price for their shares.”
The Briscoe Law Firm, PLLC is a full service business litigation and shareholder rights advocacy firm with more than 20 years of experience in complex litigation and transactional matters.Powers Taylor, LLP is a boutique litigation law firm that handles a variety of complex business litigation matters, including claims of investor and stockholder fraud, shareholder oppression, shareholder derivative suits, and security class actions.